We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+35.89%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.8B
AUM Growth
+$7.91M
Cap. Flow
-$287M
Cap. Flow %
-15.97%
Top 10 Hldgs %
51.42%
Holding
93
New
31
Increased
19
Reduced
14
Closed
21

Top Buys

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$72.8M
2
INCY icon
Incyte
INCY
+$61.9M
3
IDXX icon
Idexx Laboratories
IDXX
+$41.1M
4
ARGX icon
argenx
ARGX
+$40.5M
5
PODD icon
Insulet
PODD
+$37.5M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$437M
2
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$150M
3
IMGN
Immunogen Inc
IMGN
+$45.9M
4
LLY icon
Eli Lilly
LLY
+$37.6M
5
CYTK icon
Cytokinetics
CYTK
+$34.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.6%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
26
Boston Scientific
BSX
$65.8B
$24.2M 1.35%
353,851
+222,851
+170% +$14.3M
IMTX icon
27
Immatics
IMTX
$1.24B
$22.7M 1.27%
2,163,646
-805,393
-27% -$9.39M
SILK
28
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$21.8M 1.21%
+1,189,024
New +$18.9M
COGT icon
29
Cogent Biosciences
COGT
$6.79B
$16.1M 0.9%
+2,400,771
New +$14.8M
EXAS
30
DELISTED
Exact Sciences
EXAS
$15.8M 0.88%
+229,481
New +$14.5M
ALNY icon
31
Alnylam Pharmaceuticals
ALNY
$36.3B
$15.4M 0.86%
+103,036
New +$17.2M
IMNM icon
32
Immunome
IMNM
$2.52B
$14.7M 0.82%
+594,396
New +$12.1M
PHVS icon
33
Pharvaris
PHVS
$2.39B
$13.5M 0.75%
584,672
+74,231
+15% +$1.97M
MRNS
34
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$12.7M 0.71%
1,401,053
-371,646
-21% -$3.61M
SVRA icon
35
Savara
SVRA
$1.13B
$11.7M 0.65%
2,347,261
-35,574
-1% -$172K
SWAV
36
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$11.4M 0.63%
+35,000
New +$8.59M
KURA icon
37
Kura Oncology
KURA
$922M
$10.7M 0.6%
501,940
-1,165,381
-70% -$22.7M
ROIV icon
38
Roivant Sciences
ROIV
$25.2B
$10.6M 0.59%
+1,001,704
New +$10.8M
AXNX
39
DELISTED
Axonics, Inc. Common Stock
AXNX
$10.3M 0.57%
+149,385
New +$10.1M
MRNS
40
PUT
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$9.04M 0.5%
+1,000,000
New +$9.72M
MRNS
41
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$7.73M 0.43%
854,700
+754,700
+755% +$7.34M
PEPG icon
42
PepGen
PEPG
$133M
$7.4M 0.41%
503,624
+480,586
+2,086% +$5.68M
CABA icon
43
Cabaletta Bio
CABA
$439M
$7.33M 0.41%
429,746
+351
+0.1% +$7.53K
ESTA icon
44
Establishment Labs
ESTA
$2.72B
$7.19M 0.4%
141,162
+138,110
+4,525% +$5.54M
ACHV icon
45
Achieve Life Sciences
ACHV
$626M
$6.9M 0.38%
+1,518,230
New +$6.74M
SLNO
46
DELISTED
Soleno Therapeutics
SLNO
$6.45M 0.36%
150,775
+149,575
+12,465% +$6.77M
FDMT icon
47
4D Molecular Therapeutics
FDMT
$526M
$6.31M 0.35%
+198,186
New +$5.06M
NXTC icon
48
NextCure
NXTC
$17.3M
$5.96M 0.33%
222,655
– –
AVTR icon
49
Avantor
AVTR
$7.81B
$5.94M 0.33%
+232,446
New +$5.53M
MDGL icon
50
Madrigal Pharmaceuticals
MDGL
$12.6B
$5.08M 0.28%
+19,029
New +$4.48M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2024 Portfolio in Review

As of Q1 2024, Sofinnova Investments held 93 positions worth $1.8B, up 0.44% from $1.79B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sofinnova Investments withdrew a net $287M in Q1 2024, closing 21 positions and reducing 14 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $437M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Consumer Staples.

Against the trend, Sofinnova Investments opened a new position in Novo Nordisk worth $78.6M.

  • Sofinnova Investments's largest Q1 2024 buy was Novo Nordisk: 611,884 shares worth $78.6M.
  • Sofinnova Investments added most to Incyte in Q1 2024, an estimated $61.9M increase.
  • Sofinnova Investments's biggest Q1 2024 reduction was IDEAYA Biosciences, cutting an estimated $29.1M.
  • Sofinnova Investments fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $437M.
  • Sofinnova Investments's ten largest holdings make up 51% of its $1.8B portfolio in Q1 2024.
  • Sofinnova Investments opened 31 new positions and closed 21 in Q1 2024.
  • Sofinnova Investments's portfolio value rose 0.44% quarter-over-quarter to $1.8B.

Based on Sofinnova Investments's 13F filing for Q1 2024, filed 15 May 2024.